The rapid evolution of immunodermatology has given clinicians unprecedented tools to treat complex skin conditions, but it has also introduced a new matrix of clinical decisions. At the 2nd Annual Elevate-Derm Rapids Conference in Ft. Lauderdale, FL, Victoria Garcia Albea, a dermatology nurse practitioner, sat down with pediatric dermatology expert Dr. Lisa Swanson to unpack the practical, real-world nuances of using JAK inhibitors, managing shingles risks, and optimizing treatments for vitiligo and alopecia areata.
Oral JAK inhibitors are highly effective, but they carry a known, dose-dependent risk of Varicella Zoster Virus (VZV) reactivation. This creates a clinical hurdle regarding vaccination timing and eligibility.
According to current guidelines, patients are eligible for the recombinant shingles vaccine (Shingrix) if they are:
Crucially for clinical practice, prescribing an oral JAK inhibitor qualifies a patient under insurance guidelines to receive the vaccine starting at age 19. Beyond dermatologic safety, Dr. Swanson highlighted emerging data suggesting that the shingles vaccine may help reduce the long-term risk of dementia—giving patients and providers an extra incentive to prioritize the shot.
The clinical challenge intensifies in pediatric spaces, particularly when using oral JAKs to treat adolescents (ages 12–17) with severe alopecia areata or atopic dermatitis. Because these patients are under 19, they do not qualify for the shingles vaccine.
Interestingly, Dr. Swanson noted that while the risk of reactivation exists on oral JAKs, the pediatric shingles cases she diagnoses in her practice occur almost exclusively in children with completely competent, normal immune systems who are not on any immunosuppressive therapy.
This trend became more noticeable following the widespread adoption of the chickenpox vaccine. Two leading theories explain this phenomenon:
In pediatric patients, shingles presents with a completely different clinical profile than it does in adults:
| Clinical Feature | Adult Shingles | Pediatric Shingles |
| Primary Symptom | Intense, debilitating pain; post-herpetic neuralgia. | Asymptomatic or mild itchiness; pain is incredibly rare. |
| Morphology | Prominent, fluid-filled vesicles on an erythematous base. | Less prominent blistering; presents more as dermatomal redness with deeper red papules. |
| Distribution | Primarily trunkal/intercostal. | Can appear virtually anywhere on the body with no preferred location. |
| Systemic Symptoms | Rarely alters baseline energy unless severe. | Children often feel generally unwell, fatigued, or "not themselves." |
Because it lacks classic pain and prominent blistering, pediatric shingles is frequently misdiagnosed as allergic contact dermatitis (e.g., a strange linear poison ivy streak). The key to diagnostic clarity is identifying its strict unilaterality and dermatomal distribution.
While missing the diagnosis rarely harms the child—as the virus resolves spontaneously without causing post-herpetic neuralgia or post-herpetic pruritus—the primary risk is epidemiological. A child with active shingles can transmit the virus to others, causing chickenpox in non-immune individuals. It is vital to keep these children away from pregnant women and infants under the age of one (who have not yet received their first varicella vaccine).
Topical JAK inhibitors, specifically Ruxolitinib cream, have revolutionized vitiligo management. To optimize outcomes, Dr. Swanson pairs topical Ruxolitinib with an over-the-counter supplement: HelioCare (Polypodium leucotomos), a natural fern leaf extract native to South and Central America.
Polypodium leucotomos is primarily known as an oral antioxidant that protects the skin from UV damage, making it highly effective for sun-sensitive conditions like polymorphous light eruption (PMLE), solar urticaria, dermatomyositis, and cutaneous lupus.
Counterintuitively, while it protects against sun damage, studies show it actually potentiates the benefits of light therapy for conditions requiring repigmentation or clearance, such as psoriasis and vitiligo. Because topical Ruxolitinib works best in sun-exposed areas, adding oral HelioCare maximizes the regimen's efficacy.
HelioCare is safe for all ages at a standard dose of one capsule daily taken in the morning. For young children who cannot swallow the large capsules, the shells can be opened and the powder sprinkled directly into food or juice (orange juice is a patient favorite). Because brick-and-mortar pharmacies often stock it only during the summer months, patients should be directed to online retailers for year-round compliance.
Note on Topicals: While some European formulations have begun incorporating Polypodium leucotomos into topical creams, Dr. Swanson cautions that topical efficacy has not been clinically validated in the peer-reviewed literature. The brand-name oral HelioCare remains the gold standard utilized in clinical trials.
When a patient achieves 100% repigmentation on twice-daily Ruxolitinib, long-term maintenance becomes the priority. Clinical trial data show that maintaining a twice-daily application prevents recurrence, but real-world patients often lose motivation once their pigment returns.
If a patient stops Ruxolitinib entirely, the literature indicates roughly a 30% chance of vitiligo recurrence. To combat this, Dr. Swanson utilizes a proactive step-down strategy:
The Maintenance Shift: Stop Ruxolitinib and switch the patient to topical Tacrolimus applied twice a day, but only two days a week (e.g., weekends only). This specific protocol slashes the recurrence rate from 30% down to just 10%.
As ongoing maintenance trials mature, future protocols will likely favor a tapered dosing schedule of Ruxolitinib itself (e.g., 2–3 days per week) rather than switching molecules.
Managing severe alopecia areata requires a deep understanding of both therapeutic options and the intense psychosocial toll the disease takes on families.
When topicals fail, and a patient has too much hair loss for intralesional corticosteroid injections to be practical—or when a family is not yet ready to commit to a systemic JAK inhibitor—Dr. Swanson utilizes a highly effective intermediate regimen combining pulse oral steroids with low-dose oral minoxidil.
In daily clinical documentation, the SALT (Severity of Alopecia Tool) score remains the gold standard, primarily because it aligns with clinical trial data and insurance authorization mandates. However, SALT scores do not capture the profound psychological burden of the disease.
Because alopecia areata visits are frequently accompanied by immense grief and tears, Dr. Swanson recommends scheduling these appointments as the final slots of the morning or afternoon blocks. This allows families the unhurried time they need to process their emotions with a team that understands their disease. Fortunately, the introduction of oral JAK inhibitors has transformed these encounters; when the hair returns, those tears turn into profound, career-affirming joy.
Because the teratogenic risks of JAK inhibitors remain undetermined, strict pregnancy counseling is necessary for female patients of childbearing potential.
For patients needing to delay JAK therapy due to near-term family planning, checking a baseline serum IgE level can open alternative doors. Data indicate that if a patient's baseline IgE is greater than 200, there is a strong probability that Dupilumab (which has an excellent safety profile in pregnancy registries) will successfully treat their alopecia areata off-label.
If a patient must discontinue an oral JAK inhibitor to complete a pregnancy, clinicians can offer reassurance regarding long-term efficacy. Data from baricitinib withdrawal trials demonstrate that when patients experience a relapse during a treatment holiday, they recapture their previous clinical success beautifully upon restarting the medication, following the exact same timeline as their initial treatment course.
However, providers must remain mindful of the gendered emotional realities of a relapse. While a male patient's hair is typically short enough to reach his baseline length within a few months of restarting a JAK, a female patient with shoulder-length hair faces a much longer, emotionally trying timeline as new growth slowly catches up to the rest of her hair.
From managing insurance-approved Shingrix access for young adults to exploring cutting-edge fertility conversations (such as elective egg harvesting and surrogacy for patients who refuse to delay systemic therapy), the contemporary dermatologic landscape is both complex and incredibly rewarding. As Dr. Swanson summarized, we are living through a magical, unprecedented era where clinicians finally possess the therapeutic power to completely rewrite the lives of patients suffering from severe, immune-mediated skin diseases.
Listen to the entire podcast on Apple Podcasts or Spotify